Altimmune (ALT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist

6.170
-0.160-2.53%

Close Aug 9 16:00 ET

6.150
-0.020-0.32%

Post 19:57 ET

438.51MMarket Cap-3785P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Earnings Call TranscriptsAug 10 09:03 ET
Evercore ISI Remains a Buy on Altimmune (ALT)
TipRanksAug 9 09:53 ET · Ratings
Altimmune, Inc. (ALT): A Good GLP-1 and Weight Loss Stock to Buy Now?
Yahoo FinanceAug 8 20:15 ET
Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market
TipRanksAug 8 17:55 ET · Ratings
Altimmune | 10-Q: Q2 2024 Earnings Report
SEC announcementAug 8 16:10 ET · Announcements
Express News | Altimmune Shares Are Trading Higher. The Company Reported Q2 Financial Results
BenzingaAug 8 11:12 ET

Comments

Jaguar8

Jul 25 08:52

NEWS

$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...